Your session is about to expire
← Back to Search
IMG-7289 for Blood Cell Disorders
Study Summary
This trial will study the effects of IMG-7289 on blood cell counts in patients with essential thrombocythemia or polycythemia vera who have failed other treatments.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have any ongoing infections that aren't responding to treatment.I have a higher risk of bleeding due to blood test results or a history of bleeding disorders.I am 18 years old or older.I am not allergic to IMG-7289, LSD1 inhibitors, or similar drugs.I am willing to undergo blood tests, spleen measurements, and bone marrow exams for the study.I have been diagnosed with Essential Thrombocythemia or Polycythemia Vera.I have had my spleen removed.I agree not to father a child or donate sperm for a month after my last dose.My side effects from previous treatments are mild or gone.My kidney or liver function is not significantly impaired.My fibrosis score is 2 or less, based on a specific grading system.You are expected to live for more than 36 weeks.I stopped my previous treatment for this condition 2 weeks ago, or 4 weeks ago if it was interferon.I have tried at least one standard treatment without success or could not tolerate it.I need considerable assistance and am unable to carry out any work activities.I am not taking, nor will I need, any medication that is not allowed during the trial.I am unable to make medical decisions for myself.I can swallow pills.I am currently taking MAOI medications.
- Group 1: IMG-7289 in ET and PV Patients
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Have there been any other experiments involving IMG-7289?
"Currently, 4 trials are underway to evaluate the efficacy of IMG-7289. None of them have progressed beyond Phase 3 yet. The majority of these experiments take place in Jena and Victoria, but there are 28 other research sites participating in this process too."
How many people are participating in this clinical research?
"Affirmative. Clinicaltrials.gov reveals that this investigation, which was launched on October 2nd 2020, is actively recruiting patients. 24 individuals need to be recruited from 1 medical centre for the study's completion."
Are there any available slots within this research trial for individuals to participate?
"According to clinicaltrials.gov, recruitment for this research endeavor is in full swing since it was first posted on October 2nd 2020 and revised on April 13th 2022."
What risks have been identified with the use of IMG-7289?
"As this is only a Phase 2 trial, and no efficacy data exists yet, IMG-7289 has been assessed with a safety score of 2."
Share this study with friends
Copy Link
Messenger